Physical AI for Human Biology
Anivance AI is reshaping preclinical research with a fully integrated, animal-free platform aligned with the U.S. FDA's 2025 roadmap for New Approach Methodologies (NAMs). The platform combines organ-on-chip hardware infrastructure (Chip MPS™, ICT Sensing Module™, Aeromimic MPS™), disease models for IPF, Cystic Fibrosis, COPD, Hepatic Fibrosis, and Oncology, and AI-driven decision applications for drug candidate evaluation. Partners include Moderna and Molecular Devices. Founded in 2024 by Dr. Guan-Yu Chen, headquartered at Hsinchu Biotech Park in Taiwan.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountSep 2024
Create a free account to see which investors have funded this company.
Create Free Account
Next-gen Medicare Advantage insurance plan with AI-forward medical group delivering quality and s...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
OpenAI is an AI research and deployment company dedicated to ensuring that general-purpose artifi...
